BKD Brookdale Senior Living Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BKD Stock | Fundamental Analysis & Investment Insights
NYSE
Healthcare
Medical Care Facilities
Current Price
Live
$12.95
Analyst Target
$13.88
+7.1%
Upside
52W High
$13.08
52W Low
$4.45
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$3.08B
P/E
N/A
ROE
-212.3%
Profit margin
-9.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a deeply concerning financial profile for Brookdale Senior Living (BKD), with a Piotroski F-Score of just 2/9 indicating severe weakness in fundamental health. Despite strong recent price performance (+163.2% over 1Y), the company is unprofitable (ROE: -212.27%, Profit Margin: -9.95%), carries significant liquidity risk (Current Ratio: 0.84), and has consistently missed earnings estimates—0 out of the last 4 quarters beaten, with an average surprise of -101.87%. Valuation metrics are distorted (Price/Book: -462.50, Forward P/E: -23.33) due to negative equity and earnings, while the lack of an Altman Z-Score suggests potential distress risk. Analysts rate it a 'strong_buy' but with only 4 analysts and no meaningful insider activity, the bullish sentiment lacks conviction.
Key Strengths
Revenue growth of 4.20% YoY shows modest top-line resilience in a challenging senior care environment
Gross margin of 27.57% indicates some operational efficiency at the core service level
Price/Sales ratio of 1.00 is reasonable relative to unprofitable peers in the healthcare sector
Recent price momentum is strong, with +163.2% 1-year return signaling market optimism or speculative interest
Operating margin positive at 2.36%, suggesting limited path to profitability if cost controls hold
Key Risks
Piotroski F-Score of 2/9 signals extreme financial distress and poor earnings quality
Negative book value and ROE of -212.27% indicate eroding shareholder equity and likely balance sheet insolvency
Current Ratio of 0.84 and Quick Ratio of 0.50 reveal acute liquidity risk and inability to meet short-term obligations
Consistent and severe earnings misses: 0/4 recent quarters beaten, average surprise of -101.87%
No Altman Z-Score available, combined with negative equity, raises red flag for potential bankruptcy risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
30
20
10
0
AI Verdict
High-risk, fundamentally weak company with speculative price action
Key drivers: Piotroski F-Score of 2/9, Negative ROE and book value, Persistent earnings misses, Liquidity constraints, Distorted valuation metrics
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 1.00 is not excessive for a growth-stage healthcare firm
Watchpoints
- Price/Book of -462.50 reflects negative equity
- Forward P/E of -23.33 indicates unprofitability
- Graham Number and Intrinsic Value unavailable due to negative earnings
Future
30/100
Ref Growth rates
Positives
- 4.20% YoY revenue growth suggests some demand stability
Watchpoints
- Earnings growth YoY: -84.6%
- Q/Q EPS growth: -200.0%
- No reliable earnings growth trajectory
Past
20/100
Ref Historical trends
Positives
- Some quarters showed small earnings beats (e.g., +25.6% in 2023-Q2)
Watchpoints
- 20 of the last 25 quarters missed or barely met estimates
- History of large negative surprises (e.g., -338.5% in 2020-Q1)
- No consistent earnings progression
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Operating margin slightly positive at 2.36%
Watchpoints
- Piotroski F-Score: 2/9 (Weak)
- Current Ratio: 0.84 < 1.0
- Quick Ratio: 0.50 indicates poor short-term liquidity
- ROE: -212.27% shows severe equity deterioration
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.95
Analyst Target
$13.88
Upside/Downside
+7.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BKD and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BKD
Brookdale Senior Living Inc.
Primary
|
+153.4% | +367.5% | +163.2% | +72.4% | +18.9% | +6.2% |
|
BEAM
Beam Therapeutics Inc.
Peer
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-22.9% | +66.7% | +110.7% | +73.8% | +6.0% | +6.1% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-31.3% | +1.1% | +22.8% | -12.7% | -8.3% | -7.0% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-56.9% | -68.7% | -20.7% | -28.6% | -13.3% | -4.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-23.33
PEG Ratio
N/A
P/B Ratio
-462.5
P/S Ratio
1.0
EV/Revenue
2.7
EV/EBITDA
18.07
Market Cap
$3.08B
Profitability
Profit margins and return metrics
Profit Margin
-9.95%
Operating Margin
2.36%
Gross Margin
27.57%
ROE
-212.27%
ROA
0.92%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.84
Weak
Quick Ratio
0.5
Poor
Cash/Share
$1.07
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-17
$N/A
2025-11-06
$-0.48
-181.9% surprise
2025-08-06
$-0.16
-14.8% surprise
2025-05-06
$-0.28
-108.8% surprise
Healthcare Sector Comparison
Comparing BKD against 147 companies in the Healthcare sector
(9 bullish, 56 neutral, 82 bearish)
Return on Equity (ROE)
-212.27%
This Stock
vs
-53.48%
Sector Avg
+296.9%
(Excellent)
Profit Margin
-9.95%
This Stock
vs
-20.64%
Sector Avg
-51.8%
(Weaker)
Revenue Growth
4.2%
This Stock
vs
137.13%
Sector Avg
-96.9%
(Slower)
Current Ratio
0.84
This Stock
vs
3.37
Sector Avg
-75.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BKD
Brookdale Senior Living Inc.
|
BEARISH | $3.08B | - | -212.3% | -9.9% | $12.95 | |
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
BULLISH | $3.3B | - | -9.3% | -4.3% | $26.97 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
NEUTRAL | $3.51B | 8.96 | 39.9% | 36.5% | $20.61 | |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.57B | 111.5 | 7.5% | 2.2% | $20.07 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-06 | STENGLE NIKOLAS W. | Chief Executive Officer | Stock Award | 157,731 | - |
| 2025-07-31 | HAUSMAN JOSHUA | Director | Stock Award | 12,903 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
Barclays
2026-01-22
Overweight
Overweight
B of A Securities
2026-01-06
Underperform
Buy
RBC Capital
2025-11-17
Outperform
Outperform
Barclays
2025-11-11
Equal-Weight
Overweight
Barclays
2025-11-10
Equal-Weight
Equal-Weight
Barclays
2025-08-07
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning BKD from our newsroom.
Newest → oldest
No matching news yet.